BPC-157 will give you cancer because it's pro-angiogenic

The mechanism the objection points to is genuine. BPC-157's healing activity in rodent tendon, gut, and vascular models routes through angiogenic pathways — VEGFR2-eNOS-NO axis activation, increased fibroblast migration, recruitment of vascular structure into damaged tissue. Tumor biology also depends on angiogenesis, which is why the leap to "BPC-157 will accelerate cancer growth" is a reasonable starting hypothesis to consider. The leap itself is where the argument breaks down. Pro-angiogenic *mechanism* in tissue repair contexts does not automatically translate to *tumor-promoting outcome* in cancer-prone humans for several reasons: First, angiogenesis in healing is regulated and self-limiting. The published rodent work shows BPC-157's vascular effects normalizing toward baseline once tissue repair completes; tumor angiogenesis, by contrast, depends on sustained dysregulated VEGF signaling driven by the tumor itself. The two mechanisms share a downstream pathway but operate under very different control logic. Second, the relevant population evidence does not exist. There are no large human cohorts of BPC-157 users tracked over the kind of timeframes (5–15 years) that would allow a cancer-incidence signal to emerge above population baseline. The safety record across published human exposure is small, short, and uninformative on long-tail cancer risk in either direction. Third, the cancer-mechanism literature on agents that *do* unambiguously promote tumor angiogenesis (some growth factor therapies, certain hormone-replacement contexts) is a different shape than what BPC-157's reported activity profile resembles. Drawing a straight line from "pro-angiogenic in tendon-repair models" to "carcinogenic in humans" skips the clinical-translation layer entirely. Where the critic has a real point: the absence of long-term human safety data for BPC-157 is a genuine gap, and anyone with an active or past cancer history should treat the theoretical interaction with tumor biology as serious until human evidence rules it out. The right framing is not "BPC-157 causes cancer" — it is "the human data that would settle the question does not yet exist, and the mechanism is one that warrants caution in cancer-prone populations." That is the framing the contraindications list on the BPC-157 page reflects. Where the critic loses the thread: the claim that BPC-157 *will* cause cancer treats theoretical concern as established fact. The human evidence base for BPC-157 is genuinely thin, but it is thin in both directions — there is no human trial showing it is safe long-term, and there is no human trial showing it is dangerous either. Honest risk framing means saying both.